<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04549025</url>
  </required_header>
  <id_info>
    <org_study_id>JTX-4014-202</org_study_id>
    <nct_id>NCT04549025</nct_id>
  </id_info>
  <brief_title>Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen</brief_title>
  <acronym>SELECT</acronym>
  <official_title>Phase 2 Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab, an ICOS Agonist, in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jounce Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jounce Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, open-label study to evaluate PD-1 inhibitor JTX-4014 alone and in&#xD;
      combination with vopratelimab, an ICOS agonist, in biomarker-selected adult subjects with&#xD;
      metastatic NSCLC who are PD-1/PD-L1 inhibitor naïve and have progressed on a platinum based&#xD;
      chemotherapy regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      JTX-4014 is a fully human IgG4 monoclonal antibody designed to specifically bind to PD-1 and&#xD;
      block its interaction with its ligands, PD-L1 and PD-L2, to augment anti-tumor T cell&#xD;
      activity. Vopratelimab is an agonist monoclonal antibody that specifically binds to the&#xD;
      Inducible CO-Stimulator of T cells (ICOS) to generate an anti-tumor immune response. This is&#xD;
      a Phase 2, open label study to evaluate the efficacy, safety, tolerability of JTX-4014 alone&#xD;
      and in combination with vopratelimab in biomarker-selected adult subjects with metastatic&#xD;
      NSCLC who are PD-1/PD-L1 inhibitor naïve and have progressed on a platinum based chemotherapy&#xD;
      regimen&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in measurable lesion size</measure>
    <time_frame>averaged over 9 and 18 weeks</time_frame>
    <description>Mean percent change from baseline in all measurable lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 24 months</time_frame>
    <description>ORR according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 24 months</time_frame>
    <description>PFS according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Landmark progression free survival (PFS)</measure>
    <time_frame>9months</time_frame>
    <description>Landmark progression free survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Disease control rate (DCR) according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median duration of response (DOR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Median duration of response (DOR) according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival (OS)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Median overall survival (OS)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>JTX-4104</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: JTX-4014</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JTX 4014 in combination with vopratelimab (dose level 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: JTX-4014&#xD;
Drug: Vopratelimab Other Name: JTX-2011</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JTX 4014 in combination with vopratelimab (dose level 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: JTX-4014&#xD;
Drug: Vopratelimab Other Name: JTX-2011</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JTX-4014</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>JTX 4014 in combination with vopratelimab (dose level 1)</arm_group_label>
    <arm_group_label>JTX 4014 in combination with vopratelimab (dose level 2)</arm_group_label>
    <arm_group_label>JTX-4104</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vopratelimab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>JTX 4014 in combination with vopratelimab (dose level 1)</arm_group_label>
    <arm_group_label>JTX 4014 in combination with vopratelimab (dose level 2)</arm_group_label>
    <other_name>JTX-2011</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able and willing to participate and comply with all study requirements&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of non-small cell lung cancer&#xD;
             (NSCLC) with evaluable or measurable disease according to RECIST v1.1 with at least 1&#xD;
             measurable lesion&#xD;
&#xD;
          -  Confirmed tumor RNA signature score&#xD;
&#xD;
          -  Experienced progression of locally advanced or metastatic NSCLC after 1 prior systemic&#xD;
             antineoplastic platinum-containing regimen (adjuvant therapy will count as a regimen&#xD;
             if administered within 1 year before the relapse)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Predicted life expectancy of ≥ 3 months&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  WOCBP must agree to use highly effective birth control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent anticancer treatment or subject is expected to require any other form of&#xD;
             antineoplastic therapy while on study, either approved or investigational.&#xD;
&#xD;
          -  Current or past participation in a study of an investigational agent or using an&#xD;
             investigational device in the metastatic setting&#xD;
&#xD;
          -  Chemotherapy &lt; 28 days prior to planned C1D1&#xD;
&#xD;
          -  Prior immunotherapy including, but not limited to PD-1 or PD-L1 inhibitor mAb at any&#xD;
             time, including JTX-4014; therapy with any mAb that specifically binds to ICOS,&#xD;
             including vopratelimab; or chimeric antigen receptor T cell therapy&#xD;
&#xD;
          -  Use of anticancer therapies listed below in the metastatic setting (allowed as prior&#xD;
             treatment for localized disease):&#xD;
&#xD;
               1. Biologic therapy&#xD;
&#xD;
               2. Targeted small molecule therapy&#xD;
&#xD;
               3. Organ transplantation, including allogeneic or autologous stem cell&#xD;
                  transplantation&#xD;
&#xD;
          -  Positive test for any of the following epidermal growth factor receptor gene mutations&#xD;
             in blood or tumor: Exon 18 G719A; Exon 18 G719C; Exon 18 G719S; Exon 19 Del; Exon 20&#xD;
             S768I; Exon 20 T790M; Exon 20 Ins; Exon 21 L858R; Exon 21 L861Q&#xD;
&#xD;
          -  Prior whole brain radiation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellen Hooper, MD</last_name>
    <role>Study Director</role>
    <affiliation>Jounce Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Courtney Hart</last_name>
    <phone>857 2593840</phone>
    <email>SELECT@jouncetx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Minsk City Clinical Oncology Dispensary</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yauheni Baranau</last_name>
      <email>y.baranau@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>N. N. Alexandrov National Cancer Centre</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edvard Zhavrid</last_name>
      <email>e.zhavrid@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinicki centar Republike Srpske</name>
      <address>
        <city>Banja Luka</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mirko Stanetic</last_name>
      <email>mirko.stanetic@kc-bl.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinicki centar Univerziteta u Sarajevu</name>
      <address>
        <city>Sarajevo</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Semir Beslija</last_name>
      <email>sbeslija@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment - Dobrich AD</name>
      <address>
        <city>Dobrich</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zyuhal Kasimova</last_name>
      <email>dr.zyuhal.kasimova@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment - Uni Hospital OOD</name>
      <address>
        <city>Panagyurishte</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rossitza Krasteva</last_name>
      <email>rkr_2002@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complex Oncology Center Plovdiv</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petar Petrov</last_name>
      <email>petar_petrov_doctor@abv.bg</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krassimir Orechkov</last_name>
      <email>k_orechkov@msn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Serdika EOOD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krassimir Koynov</last_name>
      <email>kdkoynov@yahoo.co.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinicki bolnicki centar Osijek</name>
      <address>
        <city>Osijek</city>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivana Canjko</last_name>
      <email>dr.ivanamarkovic@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital Pula</name>
      <address>
        <city>Pula</city>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dragan Trivanovic</last_name>
      <email>dtrivanovic@obpula.hr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinicki bolnicki centar Split</name>
      <address>
        <city>Split</city>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Gudelj</last_name>
      <email>ivan.gudelj.1956@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinicki bolnicki centar Zagreb</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>ARENSIA Exploratory Medicine LLC / Tbilisi, Georgia</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Maglakelidze</last_name>
      <email>marina.maglakelidze@arensia-em.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Veszprem Megyei Tudogyogyintezet</name>
      <address>
        <city>Farkasgyepű</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Balazs Medgyasszay</last_name>
      <email>med.balazs@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bács-Kiskun Megyei Kórház, SZTE ÁOK Oktató Kórháza</name>
      <address>
        <city>Kecskemét</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zsolt Horváth</last_name>
      <email>horvathzso@kmk.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz</name>
      <address>
        <city>Székesfehérvár</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zsolt Pápai-Székely</last_name>
      <email>zsoltpapai@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunta Purkalne</last_name>
      <email>gunta.purkalne@stradini.lv</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Riga East Clinical University Hospital, Latvian Oncology Center</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zanete Zvirbule</last_name>
      <email>zanete.zvirbule@aslimnica.lv</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology, ARENSIA Exploratory Medicine</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iurie Bulat</last_name>
      <email>iurie.bulat@arensia-em.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affidea Romania SRL</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Prof Dr I Chiricuta Institute of Oncology</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tudor Ciuleanu</last_name>
      <email>tudor_ciuleanu@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Sf. Apostol Andrei Constanta</name>
      <address>
        <city>Constanţa</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Mazilu</last_name>
      <email>lauragrigorov@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Center Sfantul Nectarie</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Schenker</last_name>
      <email>mike_schenker@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arkhangelsk Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Arkhangel'sk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Nechaeva</last_name>
      <email>chemother29@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalya Fadeeva</last_name>
      <email>89048082445@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guzel Mukhametshina</last_name>
      <email>gzm_kazan@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk Regional Oncology Center n.a. A.I. Kryzhanovskiy</name>
      <address>
        <city>Krasnoyarsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruslan Zukov</last_name>
      <email>zukov_rus@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kursk Regional Oncology Centre</name>
      <address>
        <city>Kursk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Lifirenko</last_name>
      <email>pikood@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vitamed</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Poddubskaya</last_name>
      <email>podd-elena@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nizhniy Novgorod City Oncology Center</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Matrosova</last_name>
      <email>marinamatrosova52@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Oncology Dispensary</name>
      <address>
        <city>Omsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rinat Galiulin</last_name>
      <email>galiulin_rinat@bk.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evromedservis LCC</name>
      <address>
        <city>Pushkin</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantin Penkov</last_name>
      <email>penkov76@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ryazan State Medical University n.a. I.P. Pavlov</name>
      <address>
        <city>Ryazan'</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgeniy Kulikov</last_name>
      <email>ruonco@rambler.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First St. Petersburg State Medical University n.a. I.P Pavlov</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrey Akopov</last_name>
      <email>akopovand@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GBUZ Saint Petersburg Clinical Research Center of Specialized Types of Care (Oncology)</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fedor Moiseenko</last_name>
      <email>moiseenkofv@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JSC &quot;Current medical technologies&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svetlana Odintsova</last_name>
      <email>odin-svet@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mordovia State University</name>
      <address>
        <city>Saransk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Skopin</last_name>
      <email>skopinpi@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Oncology Institute of Tomsk Scientific Center</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Goldberg</last_name>
      <email>goldbergve@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Volgograd Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Volgograd</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadezhda Kovalenko</last_name>
      <email>kovalenkost@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Oncology Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolay Kislov</last_name>
      <email>nikovik@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia - PPDS</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milica Kontic</last_name>
      <email>milicakontic@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Bezanijska Kosa</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoran Andric</last_name>
      <email>drzoranandric@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute for Oncology and Radiology of Serbia - PPDS</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davorin Radosavljevic</last_name>
      <email>davorr@ncrc.ac.rs</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Petrovic</last_name>
      <email>drmarinapetrovic@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Lung Diseases Vojvodina</name>
      <address>
        <city>Sremska Kamenica</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bojan Zaric</last_name>
      <email>bojanzaric@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodny onkologicky ustav</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Godal</last_name>
      <email>robert.godal@nou.sk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vychodoslovensky onkologicky ustav, a.s.</name>
      <address>
        <city>Košice</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuzana Pribulova</last_name>
      <email>pribulova@vou.sk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Adana Sehir Egitim ve Arastirma Hastanesi</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timucin Cil</last_name>
      <email>drtimucincil@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akdeniz University Medical Faculty</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hasan Coskun</last_name>
      <email>hs.coskun@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Trakya Universitesi Saglik Arastirma ve Uygulama Merkezi Hastane</name>
      <address>
        <city>Edirne</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irfan Cicin</last_name>
      <email>irfancicin@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul University Cerrahpasa Medical Faculty</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mustafa Ozguroglu</last_name>
      <email>ozguroglu@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>T.C. Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin City Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahmut Gumus</last_name>
      <email>mgumus@superonline.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tip Fakultesi Hastanesi</name>
      <address>
        <city>İzmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tuncay Goksel</last_name>
      <email>tuncaygoksel33@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Izmir Medicalpark Hospital</name>
      <address>
        <city>İzmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cagatay Arslan</last_name>
      <email>arslancagatay@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inonu University Faculty of Medicine Turgut Ozal Medical Center</name>
      <address>
        <city>Malatya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harkan Harputluoglu</last_name>
      <email>harputlu@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Nonprofit Enterprise Cherkasy Regional Onсology Dispensary of Cherkasy Oblast Council</name>
      <address>
        <city>Cherkasy</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viktor Parmanov</last_name>
      <email>paramonov.vik@ukr.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Non-profit Enterprise City Clinical Hospital #4 of Dnipro City Council - PPDS</name>
      <address>
        <city>Dnipro</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Bondarenko</last_name>
      <email>oncology@dsma.dp.ua</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise &quot;SubCarpathian Clinical Oncological Centre of Ivano-Frankivsk RC&quot;</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vasyl Boyko</last_name>
      <email>vboyko65@ukr.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arensia Kapitanivka - PPDS</name>
      <address>
        <city>Kapitanivka</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valeriy Cheshuk</last_name>
      <email>v.cheshuk@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Non-profit Enterprise Regional Center of Oncology</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleh Kobziev</last_name>
      <email>olegkobzev@ukr.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SI Institute of Medical Radiology and Oncology n.a. S.P. Hryhoriev of NAMS of Ukraine</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Muzhychuk</last_name>
      <email>muzhichukivan@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNPE Khmelnytskyi Regional Antitumor Center of Khmelnytskyi Regional Council</name>
      <address>
        <city>Khmelnytskyi</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignor Drobner</last_name>
      <email>drobneri@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Private Enterprise Private Manufacturing Company Acinus</name>
      <address>
        <city>Kropyvnytskyi</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grygorii Ursol</last_name>
      <email>doctor.ursol25006@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Nonprofit Enterprise Kyiv City Clinical Oncological Center</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmytro Osynskyi</last_name>
      <email>dosinsky@ukr.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyiv Railway Clinical Hospital #3 of Branch Health Center of the PJSC Ukrainian Railway</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman Vereshchako</last_name>
      <email>susarromver@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Modern Cancer Care Hospital &quot;LISOD&quot;</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dinara Ryspayeva</last_name>
      <email>ryspayeva1@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Institute of Cancer</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuriy Ostapenko</last_name>
      <email>yuriy.v.o1974@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Municipal Enterprise Volyn Regional Medical Oncology Centre of the Volyn Regional Council</name>
      <address>
        <city>Luts'k</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Sinelnikov</last_name>
      <email>ivan.sinielnikov@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MNPE Central City Clinical Hospital of Uzhhorod City Council</name>
      <address>
        <city>Uzhhorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yevhen Hotko</last_name>
      <email>yhotko@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Bosnia and Herzegovina</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Georgia</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Moldova, Republic of</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Turkey</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

